ArticleLeukemia2024
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Abstract readLetter
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Blood advances · 2026Article
- Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.Blood advances · 2026Article
- Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.Cancers · 2026Review
- Age-specific mutation profiles and their prognostic implications in pediatricHaematologica · 2026Article
- Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia.The FEBS journal · 2026Review
- Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.Cancer medicine · 2026Article
- Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.bioRxiv : the preprint server for biology · 2025Article
- Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.Cancer medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 12 institutions in 1 country.
Shinju Iyoda *Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kenichi Yoshida *Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-4612-2778
Kota Shoji *Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nana ItoHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Miu TanakaHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Genki YamatoDepartment of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan.ORCID 0000-0003-4000-0753
Shinichi TsujimotoDepartment of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID 0000-0001-5738-4138
Norio ShibaDepartment of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yasuhide HayashiInstitute of Physiology and Medicine, Jobu University, Takasaki, Japan.
Yusuke ShiozawaLaboratory of Molecular Analysis, Nippon Medical School, Tokyo, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Kenichi ChibaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Ai OkadaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Hiroko TanakaDepartment of Integrated Analytics, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Satoru MiyanoDepartment of Integrated Analytics, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0002-1753-6616
Yuhki KogaDepartment of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Hiroshi MoritakeDivision of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0001-5471-7646
Kiminori TeruiDepartment of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID 0000-0003-1294-8635
Etsuro ItoDepartment of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID 0000-0002-0168-2475
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0001-9310-2126
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0003-1520-7007
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.ORCID 0000-0003-0525-4766
Akio TawaDepartment of Pediatrics, Higashiosaka Aramoto Heiwa Clinic, Higashiosaka, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-2452-6520
Momoko NishikoriHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Souichi AdachiHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hidemasa MatsuoHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. matsuo@kuhp.kyoto-u.ac.jp.ORCID 0000-0002-7578-006X
Kyoto University · JPHirosaki University · JPNational Center For Child Health and Development · JPTokyo Medical and Dental University · JPYokohama City University · JPGunma University · JPJobu University · JPKanagawa Children's Medical Center · JPKyushu University · JPNippon Medical School · JPShiga University of Medical Science · JPUniversity of Miyazaki · JP
Funding
Japan Agency for Medical Research and Development (AMED) Practical Research for Innovative Cancer ControlJapan Agency for Medical Research and Development (AMED) Project for Cancer Research and Therapeutic EvolutionJapan Agency for Medical Research and Development (AMED) Project for Development of Innovative Research on Cancer TherapeuticsMEXT | Japan Society for the Promotion of Science (JSPS) JP19K16832MEXT | Japan Society for the Promotion of Science (JSPS) JP22K08475MEXT | Japan Society for the Promotion of Science (JSPS) JP23K07264
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene RearrangementHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMutationMyeloid-Lymphoid Leukemia ProteinProto-Oncogene Proteins p21(ras)AdultAgedFemaleHumansMaleMiddle AgedPrognosisYoung AdultHistone-Lysine N-MethyltransferaseKMT2A protein, humanKRAS protein, humanMyeloid-Lymphoid Leukemia ProteinProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.